Love Maharashtra? Then you wil love Marathikatta!
Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                    Movies   Aviation   Pharma   About Us   Feedback   Links
RANBAXY - ZANOTECH PACT ON CANCER DRUGS
 


Ranbaxy in pact with Zenotech on cancer drugs

Ranbaxy will market Zenotech's oncology cytotoxic injectable products under the Ranbaxy label in Latin America, Russia and other CIS markets.

BY OUR PHARMA CORRESPONDENT
March 25, 2006

Ranbaxy Laboratories Ltd, India's number one drugmaker, said it has entered into a strategic alliance Zenotech Laboratories on cancer drugs.

Under the terms of the semi-exclusive agreement, Ranbaxy will market the Hyderabad-based Zenotech's oncology cytotoxic injectable products under the Ranbaxy label in the key markets of Latin America, including Brazil and Mexico, along with Russia and other CIS markets.

Ranbaxy was also exploring the possibility of expanding the collaboration to include other markets. Zenotech will develop and manufacture the oncology products at the company's facilities in India.

Zenotech is a speciality generic injectables company with a biotech core. Its injectables product portfolio concentrates on niche therapy areas such as oncology, anaesthesiology, gynaecology and neurology. The company has a direct marketing presence in India and Vietnam, and has subsidiaries in Brazil and Nigeria. Zenotech's generic biologicals, GM-CSF and G-CSF, have completed clinical trials in India and are awaiting regulatory approvals.

The company has research and development facilities in India and the United States.

Ranbaxy commented that the agreement would enable it to enter a new therapeutic segment for it in the markets, and will enable the firm to continue strengthening its product portfolio and provide novel products. Ranbaxy already has a presence in the oncology segment in India, selling its oncology portfolio there through its Super Specialties division.

Zenotech added that the deal was beneficial for it because it would help it to expand its market reach in several emerging markets around the world. The alliance will help Zenotech speed up its biogenerics development programme.

More related stories from Pharma


Healing prayers no cure for the ill, says study

Pulmonary hypertension drug PulmoLAR in human trial

Pharma markets in China, Korea, Mexico, Russia & Turkey gather pace

Pfizerís anxiety drug Lyrica gets EU nod

Asymmetrical breasts: A presage to cancer?

Dream to eradicate polio still far off

GlaxoSmithKline loses fluticasone case

Able files recast plan with bankruptcy court

Ranbaxy in pact with Zenotech on cancer drugs

Lupin and Aspen to form JV on TB drugs

Blood cancer drug Ceflatonin gets orphan drug status

Bangladesh to set up API park; to export drugs worth Tk 8.50 cr to Burma

Wockhard Limited: A profile
Cipla Ltd company profile

 

 

 

Auto news for auto freaks! iDrive.in
DWS community! / Cricket blog

 

Latest Stories in Pharma

 Vertex commences phase II studies for Aurora kinase inhibitor VX-680

GlaxoSmithKline starts H5N1 avian flu vaccine trials in Germany, Belgium

Novartis acquires rights for two drug leads

Serono plans major acquisitions

Samaritan to sell Amphocil in Greece

HIV infection cases fall in South India

Flu drug: Erimos, NC State University seek patent for EM-1421

HollisterStier inks pact with Prism Pharma on cardiovascular drug PM101

Erbitux approved for head and neck cancer in Europe

EPIX Pharmaceuticals merges with Predix

Avanir's involuntary emotional expression disorder (IEED) drug Neurodex gets priority review

 Death of women raises alarm on abortion pillís safety

Prestwick gets approvable letter for Xenazine for treatment of chorea with HD

Nexavar - Kidney cancer drug gets Swiss nod

Anti-rejection drug Prograf approved in US

 

Latest Stories in Pharma

Archived Pharma stories

 

Latest updates    Contact Us - Feedback    About Us